参考文献: Peter Schmid, et al.Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple-Negative Breast Cancer: Updated Event-Free Survival Results From the Phase 3 KEYNOTE-522 Study. 2023 SABCS abstract #LBO1-01. 审校:Faline 排版:F...
(LBO1-01) Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 stu...
2. Schmid P, Cortés J, Dent RA, et al. LBA18 Pembrolizumab or placebo plus chemotherapy followed by Pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study. Ann Oncol. 2023;34(suppl 2):S1257. doi:10.1016/j.annonc.2023.10.008 3. Schmid ...
Updated findings from the study were presented at the 2024 ESMO Congress and showed Results from the phase 3 KEYNOTE-522 trial (NCT03036488) in patients with early-stage triple-negative breast cancer (TNBC) showed that neoadjuvant pembrolizumab with chemotherapy, followed by adjuvant pembrolizumab, ...
4.Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomis...
(LBO1-01) Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study 中文标题: (LBO1-01)新辅助帕博利珠单抗或安慰剂加化疗后辅助帕博利珠单抗...
1、Schmid P, et al. Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase 3 KEYNOTE-522 study. ESMO Congress 2023, LBA18 2、Gianni L, et al. Event-free survival (EFS) analysis of neoadjuvant taxane/carboplatin...
研究标题:(LBO1-01) Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study 中文标题:(LBO1-01)新辅助帕博利珠单抗或安慰剂加化疗后辅助帕博...
Peter Schmid, MD, PhD, discusses his key takeaways from the phase 3 KEYNOTE-522 trial and the updated findings presented at the 2024 ESMO Congress. Peter Schmid, MD, PhD, of Barts Cancer Institute at Queen Mary University in London, United Kingdom, discusses his key takeaways from thephas...
KEYNOTE-522 研究 5 年随访数据揭晓,帕博利珠单抗+化疗方案优势仍在延续 LBO1-01Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study ...